How high-density lipoprotein function is affected in patients with inflammatory muscle diseases
Altered High-Density Lipoprotein function in Patients with Idiopathic Inflammatory Myopathies
This study is looking at how a type of good cholesterol called HDL, which usually helps keep your blood vessels healthy, doesn't work properly in people with idiopathic inflammatory myopathies (IIM), and it aims to find out why this happens and how it might lead to heart problems, so we can discover new ways to help.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10908701 on NIH RePORTER |
What this research studies
This research investigates how high-density lipoproteins (HDL), which usually protect blood vessels, become dysfunctional in patients with idiopathic inflammatory myopathies (IIM). The study aims to understand the mechanisms behind vascular damage in these patients, particularly focusing on the role of HDL and its antioxidant properties. Researchers will explore the relationship between HDL function, inflammation, and the gut microbiome to identify potential therapeutic targets. By analyzing blood samples and gut microbiome profiles, the study seeks to uncover new insights into cardiovascular risks associated with IIM.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic inflammatory myopathies.
Not a fit: Patients with other autoimmune diseases not related to inflammatory myopathies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that protect against cardiovascular disease in patients with inflammatory muscle diseases.
How similar studies have performed: Previous research has shown promising results in understanding HDL dysfunction in other inflammatory conditions, suggesting potential for success in this novel approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Bae, Sangmee — University of California Los Angeles
- Study coordinator: Bae, Sangmee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.